Compass Pathways Plc ADR
Closed
12.49 -1.26
Overview
Share price change
24h
Min
12.33
Max
13.48
Income | 185M 91M |
|---|---|
EPS | -0.3 |
Employees | 156 |
EBITDA | 139M 93M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +85.77% upside |
Next Earnings | 30 Jul 2026 |
|---|
Market Cap | 428M 1.7B |
|---|---|
Previous open | 13.75 |
Previous close | 12.49 |
Compass Pathways Plc ADR Chart
Past performance is not a reliable indicator of future results.
About Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
